Device and method for treating organometallic proteins of biological tissue cells by supplying specific photon quanta

Abstract

A system of medical devices for a Quantum Bio-Modulation (QBM) treatment of functional biological tissue cells, comprising: - a laser source configured to produce photons according to adjustable time and power wavelength parameters; - at least one optical distributor; and - at least one diffuser.

Description

[0001] Device and method for the treatment of organometallic proteins of biological tissue cells by supplying specific photon quanta

[0002] Technical field

[0003] The invention is in the field of photobiomodulation (PBM) and relates more particularly to the delivery of specific photon quanta to the organometallic proteins of biological tissue cells, and to living tissues.

[0004] Prior art

[0005] PBM, which has followed a linear trajectory for decades, remains poorly defined. According to the North American Association for Photobiomodulation Therapy (NAALT) or the World Association for Laser Therapy (WALT), the term photobiomodulation therapy (PBMT) was recognized in 2014. The latter is defined as a therapy that brings energy from photons into contact with or at a short distance from the skin in such a way as to make this photonic energy penetrate a few millimeters to reach damaged or diseased tissues at the level of organometallic proteins such as cytochrome c-oxidase of mitochondria present in the cells of these tissues. The result of this photon-organometallic protein interaction results in what is called the PBM effect.

[0006] Summary of the invention

[0007] In a first aspect, the invention provides a medical device system for Quantum Bio Modulation (QBM) treatment of functional biological tissue cells, comprising:

[0008] - a laser source configured to produce photons according to adjustable wavelength, time and power parameters;

[0009] - at least one optical distributor; and

[0010] - at least one diffuser. In a preferred embodiment, the at least one optical distributor comprises an optical fiber inserted into a central venous line type multi-lumen catheter.

[0011] In another preferred embodiment, the at least one optical dispenser is further configured to have one or more of a list of characteristics including being implantable, being temporary, sterile, single use.

[0012] In another preferred embodiment, the at least one optical distributor comprises a plurality of optical distributors, and the plurality of optical distributors is mounted in an illumination system configured to provide illumination of tubing or an oxygenation chamber of an extracorporeal circulation circuit.

[0013] In another preferred embodiment, the at least one optical dispenser comprises a plurality of optical dispensers, and each of the plurality of optical dispensers is crimped with a detachable needle configured for insertion of the optical dispenser through a cardiac muscle.

[0014] In another preferred embodiment, the power parameters are adjustable between 1 mW and 4000 mW, and wavelengths used are in a range starting at 500 nm and ending at 1100 nm.

[0015] In a second aspect, the invention provides a method for photonic stimulation of biological tissue according to Quantum BioModulation (QBM), comprising the steps of: generating photons according to adjustable time and power parameters by means of a laser source; placing at least one optical distributor with an optical input for receiving the photons generated by the laser source and an optical output of the optical distributor oriented towards the biological tissue; delivering at least a portion of the generated photons onto the biological tissue. In a preferred embodiment, the photonic stimulation method further comprises: providing the biological tissue suspended in a liquid medium; presenting the liquid medium in a closed container or a passing conduit; and configuring the optical output of the optical distributor to be in contact with the liquid medium.

[0016] Brief description of the figures

[0017] The invention will be better understood from the following detailed description of preferred embodiments of the invention, and with reference to the figures, in which Fig. 1 contains a diagram illustrating two tight-fitting suits, one for men, the other for women according to an exemplary embodiment of the invention;

[0018] Fig. 2 contains a diagram illustrating an intravascular device for in vivo systemic treatment of circulating blood according to an exemplary embodiment of the invention;

[0019] Fig. 3 contains a diagram illustrating a device for QBM treatment of circulating blood according to an exemplary embodiment of the invention;

[0020] Fig. 4 contains a diagram illustrating an intramyocardial device for QBM treatment of acute cardiac ischemia / reperfusion injuries according to an exemplary embodiment of the invention;

[0021] Fig. 5 contains a diagram illustrating an intrathoracic device for QBM treatment of acute cardiac ischemia / reperfusion injuries according to an exemplary embodiment of the invention;

[0022] Fig. 6 contains a diagram illustrating the endoventricular medical device for QBM treatment of acute cardiac ischemia / reperfusion injury according to an exemplary embodiment of the invention;

[0023] Fig. 7A contains a diagram illustrating the intracoronary device for QBM treatment of acute cardiac ischemia / reperfusion injuries according to an exemplary embodiment of the invention;

[0024] Fig. 7B contains another variant of a device produced as an on-board and autonomous system, implanted in the ear, according to an exemplary embodiment of the invention; Fig. 7C contains another variant of a device applied to the female genital system for the management of endometriosis, dysmenorrhea, according to an exemplary embodiment of the invention;

[0025] Fig. 7D contains another variant of a device applied to the male genital apparatus for the management of erectile dysfunction, according to an exemplary embodiment of the invention; and

[0026] Fig. 8 contains a diagram illustrating the device for ex vivo QBM treatment of ischemia / reperfusion injuries, according to an exemplary embodiment of the invention.

[0027] Throughout the figures, the same or similar features will be referred to by the same reference sign wherever possible.

[0028] Detailed Description of Preferred Embodiments of the Invention The following description details specific features of the present invention according to various preferred embodiments and further describes practical fields of application of the invention. The contents of international application PCT / IB2024 / 052594, the priority of which is claimed, are incorporated herein by reference.

[0029] The effectiveness of PBM relies on the delivery, within the target tissue, of an adequate quantity of photonic energy necessary for the target cells and target tissues. The inventors sought to find the best way to deliver the most effective dose by the spatial irradiance of photonic energy within the target tissue in order to ensure the optimal effect of PBM. Indeed, current devices diffusing photonic energy do not take into account the optical properties of tissues which determine the effects of diffraction, absorption, reflection, transmission and diffusion of photons in these tissues. These devices are faced with a loss of photons (therefore energy) to pass through the different biological structures of the tissues making the PBM effect random, or even zero because the spatial irradiance is not taken into account and, consequently, the dose is not effective.Thanks to the technology of the present invention, all tissues are reachable, from the most superficial to the deepest, because the photons are delivered:

[0030] - at a distance reaching the target tissue taking into account the constraints of light propagation in the different living tissues (radiometry),

[0031] - in a sufficient and adequate quantity to obtain the expected biological effect (dosimetry).

[0032] En se basant sur une dosimétrie adaptée (Report on WP 3, Study and optimization of the photobiomodulation effects induced on mitochondrial metabolic activity of human cardiomyocytes for different radiometric and spectral conditions Date: 04 / 04 / 2024, EPFL, Dr. Jaroslava Joniovâ, Dr. Emmanuel Gerelli MER, Dr. Georges Wagnières I Study and optimization of the photobiomodulation effects induced on mitochondrial metabolic activity of human cardiomyocytes for different radiometric and spectral conditions, Jaroslava Joniova, Dr. Emmanuel Gerelli, Dr.Georges Wagnières, Life Sciences, Elsevier, Received 27 February 2024; Received in revised form 17 May 2024; Accepted 27 May 2024, Available online 31 May 2024) and adapted radiometry ( Light dosimetry in the myocadium: - Determination of the optical properties at 808 nm, - Simulation of the light propagation around a cylindrical light distributor (CLD), - Calculation of the optimal CLD-CLD distance, - Evaluation of illumination conditions combination, 17 / 05 / 2023, Aurélien Grégor, MER Dr. Georges Wagnières, Dr. Jaroslava Joniova, EPFL), the inventors were able to improve the effectiveness of PBM, for example in gas exchange (hematosis) in the context of hypoxic syndrome and in cardiac functionality in the context of cardiac ischemia / reperfusion injuries.

[0033] One of the essential characteristics of the present invention consists in the provision of a specific photonic dose to the cells of the tissues in a defined time, both on living cells or tissues, fixed (organs) or in movement (circulating blood, or in suspension in a liquid medium), making it possible to meet the cellular metabolic need, in particular therefore both to restore the functional metabolic needs of the tissues and cells and to promote their recovery or regeneration and to protect them from cytokine or environmental metabolic attacks and to optimize the processes of anti-infectious inflammatory, immunological defenses.

[0034] The contribution of an optimal photonic dose (= photonic quanta in a singular time) is absorbed specifically at the level of the organometallic proteins of the mitochondria.

[0035] This is a precise, reproducible, controlled treatment defined by radiometric and dosimetric conditions specific to each targeted tissue. This type of treatment is called QBM (Quantum Bio Modulation) or QBMT (Quantum Bio Modulation Treatment) in this document.

[0036] The device and method according to the invention can be used in a large number of non-medical extracorporeal applications, and medical clinical applications, in all areas where there is a cellular metabolic dysfunction and / or a need for recovery, cellular or tissue regeneration, protection against attacks.

[0037] In the present patent application, the invention is illustrated by several non-limiting preferred embodiments of QBMT on different target tissues, with adapted modes of delivery of light radiation, which apply in particular:

[0038] - to peripheral cutaneous, subcutaneous, muscular and osteotendinous tissues in the context of preferred embodiment of non-medical and medical extracorporeal application

[0039] - intra-circulatory with for example the delivery of a photonic dose to a circulating blood mass as in the example developed for ARDS (Acute Respiratory Distress Syndrome)

[0040] - to deep organs that cannot be reached transcutaneously, as in the developed example of the delivery of a photonic dose to cardiac tissue to treat ischemia / reperfusion. I. Use of QBM in a non-medical extracorporeal application

[0041] In the present preferred embodiment, the use of QBM treatment consists of delivering a determined photonic dose as close as possible to the skin surface by a device carrying fiber optic distributors or LEDs on its internal face with a choice of wavelength, power and delivery mode individually adapted according to the target tissue to obtain a topical and / or systemic effect, where we control the dose in order to have an effect optimized for safety, efficacy and reproducibility.

[0042] The wavelengths used are between 500 nm and 1100 nm, allowing optimal absorption of photons on tissues or cell elements, as the case may be.

[0043] The power of the sources used varies between 1 mW and 4000 mW, allowing optimal illumination of the maximum amount of tissue and / or elements in an athermal manner. The power is emitted (continuously or pulsed) according to the time required to illuminate the targeted mass of tissue with optimal efficiency. The treatment can be carried out in intermittent or sequential cycles or continuously for a short or prolonged period (chronic treatment), the aim being to treat the number of tissue masses necessary to obtain the desired effect.

[0044] In this example, the medical device according to the invention, for a Quantum Bio Modulation (QBM) treatment of biological tissue cells, comprises:

[0045] • a laser source (number 1, figure 1) configured to produce photons according to adjustable time and power parameters and adapted to the optical distributor. This laser source can be transportable (internal or external) or fixed.

[0046] • at least one optical distributor (number 2, figure 1) which will ensure the transmission of light to the optical diffuser. • at least one optical diffuser (number 3, figure 1) which will ensure the diffusion of isotropic light and which will be fixed relative to the skin or mucous tissue in order to control the radiometric conditions required to guarantee the optimal dose.

[0047] The optical distributors and diffusers will be incorporated into a Spandex-type fabric to optimize the light application conditions.

[0048] One of our products is a pajama-type combination that will allow the application of photonic doses adapted to the targeted tissue effect on the target tissue mass on a targeted part or on the maximum body surface on the entire body with the aim, for example, of ensuring better muscle recovery while protecting our epidermis, dermis and hypodermis, or for example of targeting all or part of the osteotendinous and / or joint apparatus or the dermo-epidermal tissues. This type of product makes it possible to guarantee optimal effectiveness of the QBM to promote recovery and healing and / or slow down the senescence processes of the target muscle and / or osteotendinous and / or dermo-epidermal tissues.

[0049] Figure 1 contains a diagram illustrating two skin-tight suits, one for men (left) and one for women (right). These suits diffuse light homogeneously over the entire body thanks to the integration of a network of diffusers 3 (LEDs or interconnected optical fibers), which is connected to a laser source 1 via optical distributors 2.

[0050] Other application examples: skin and subcutaneous aging, dermal lesions (radiodermatitis, burns, ulcers, pressure sores), tendinopathies, osteoarticular lesions, muscle recovery, muscle injuries.

[0051] Another variant of this device consists of a self-contained skin-tight suit. In other words, the laser sources are integrated directly into this suit, along with the necessary batteries. II. Use of QBM in vivo and ex vivo in the bloodstream

[0052] 1. Intravascular device for in vivo systemic treatment of circulating blood

[0053] In the present preferred embodiment, the use of intravascular treatment by QBM consists of delivering a therapeutic photonic dose to the blood circulating in a known volume (example: the chamber formed by the vena cava and the atrium in the context of the treatment of ARDS) and more particularly to the formed elements of the deoxygenated (or not) circulating blood to obtain a loco-regional and systemic effect.

[0054] The wavelengths used are between 500 nm and 1100 nm, allowing optimal absorption of photons on the organometallic proteins present in the formed elements of circulating blood (hemoglobin, red blood cells and white blood cells).

[0055] The power of the sources used varies between 1 mW and 4000 mW, allowing the maximum number of elements circulating in the blood to be illuminated athermally. The power emitted varies according to the time required to illuminate at least 1 blood mass (determined according to the patient's sex, weight and height). The treatment can be carried out in intermittent or sequential cycles or continuously for a short or prolonged period (chronic treatment), the aim being to treat the number of blood masses necessary to obtain the desired effect.

[0056] Example for the treatment of ARDS by QBM

[0057] The device according to the invention, when used to treat certain forms of Acute Respiratory Distress Syndrome (ARDS), can be configured to deliver light intravascularly into a defined blood volume whose contents are constantly renewed by the circulation of blood, a volume between the vena cava and the atrium, the circulation of blood in this volume thus making it possible to treat the entire mass of blood entering the pulmonary system in a relatively limited time. This results in numerous advantages, in particular:

[0058] • To improve dosimetric conditions, by diffusing light directly into the volume concerned because there is no tissue to pass through.

[0059] • To directly illuminate the circulating elements of deoxygenated blood, including organometallic proteins, as close as possible to the alveolar-capillary barrier, so that the treated circulating blood elements come into direct contact with the entire affected lung surface.

[0060] • To stimulate organometallic proteins such as mitochondria, hemoglobin, NADPH oxidase of circulating cells, which can also optimize the repair / regeneration processes of the alveolar-capillary barrier and induce the production and / or release of NO. This results in several positive effects, in particular: o Induction of metabolic reprogramming (Warburg effect) of leukocytes; o Inhibition of the burst of “Reactive Oxygen Species” - Reactive oxygen species (ROS) of circulating elements; o Modulation of different NO signaling pathways when circulating blood is in contact with the endothelium; o Inhibition of trans-endothelial infiltration of inflammation and edema cells downstream of illuminated areas; and o Improvement of hematosis: increased affinity of hemoglobin for oxygen.

[0061] Preclinical results obtained on an acute porcine hypoxia model show the efficacy on blood hematosis of intravascular treatment by QBM with a fiber optic distributor in a volume of circulating blood located at the junction between the superior vena cava and the right atrium for 15 minutes at 150 mW at a wavelength of 650 nm.

[0062] This treatment notably induced the following effects:

[0063] - a significant increase in the PaC>2 / FiC>2 ratio;

[0064] - an increase in the affinity of hemoglobin for deoxyhemoglobin with the improvement of p50; - an increase in the concentration of NO in the systemic circulation.

[0065] Furthermore, no serious adverse effects were observed during the QBM treatment procedure during the hypoxia phase: o no deaths; o no massive pulmonary embolism; o no vessel perforation or tamponade; o no hemorrhagic shock.

[0066] Heart rate, invasive arterial pressures, cardiac output, stroke volume, and CBC / platelets did not significantly vary between the start and end of the QBM treatment procedure during the hypoxia phase.

[0067] The device according to the invention comprises:

[0068] • a laser source (number 1, figure 2), an electro-medical device, which produces and delivers photons with parameters (time and power) adjustable by the user; and

[0069] • at least one fiber optic distributor (number 2, figure 2), composed of an optical fiber inserted into a multi-lumen catheter, of the central venous route type.

[0070] • at least one optical diffuser (number 3, figure 2) which will ensure the diffusion of isotropic light in order to control the radiometric conditions required to guarantee the correct dose.

[0071] Figure 2 contains a schematic illustrating the intravascular device for in vivo systemic treatment of circulating blood with the laser source 1, the fiber optic distributor 2 and the diffuser 3.

[0072] The intravascular placement under regulatory aseptic conditions of the fiber optic distributor is carried out percutaneously using the Seldinger technique (this technique is used routinely by medical personnel):

[0073] • Percutaneous venous access by puncture of the right jugular vein under ultrasound imaging. • Placement of the fiber optic distributor in the superior vena cava / right atrium / inferior vena cava junction.

[0074] • Fixing the catheter to the patient's skin.

[0075] • Bedside radiographic control of the correct position of the fiber optic distributor.

[0076] The fiber optic distributor is connected to the laser source to perform the processing.

[0077] Treatment can be performed in intermittent or sequential cycles or continuously for a short or prolonged period, the aim being to treat the number of blood masses necessary to achieve the desired effect.

[0078] This fiber optic distributor can therefore remain in place for several days or weeks. This type of device is preferably implantable and temporary, sterile and single-use.

[0079] Another variant of this device is an on-board, stand-alone system. In other words, the device, consisting of the diffuser and the laser source, is implanted in the superior vena cava.

[0080] 2. Device for QBM treatment of circulating blood ex vivo

[0081] The use of QBMT consists of illuminating circulating blood ex vivo in the context of extracorporeal circulation.

[0082] The wavelengths used are between 500 nm and 1100 nm, with a power varying between 1 mW and 4000 mW. The emitted power will vary according to the time required to illuminate at least 1 blood mass (determined according to the sex, weight and size of the patient). The treatment can be carried out in intermittent or sequential cycles or continuously for a short or prolonged period, the aim being to treat the number of blood masses necessary to obtain the desired effect. The system according to the invention comprises:

[0083] • a laser source (reference 1, Figure 3), electro-medical device; and

[0084] • at least one optical distributor (reference 2, Figure 3), which allows the transmission of light to the diffusers

[0085] • at least one diffuser (reference 3, Figure 3) mounted in a system which allows the tubes / cannulas or the oxygenation chamber of the extracorporeal circulation circuit to be illuminated homogeneously.

[0086] Figure 3 contains a schematic illustrating the device for QBM treatment of circulating blood ex vivo with the Laser source 1, the optical distributors 2, the diffuser (patch or band) of the tubing / cannulas 3 and a diffuser (patch or band) of the oxygenation chamber 4.

[0087] III. Use of QBM in vivo and ex vivo in organs

[0088] In the present preferred embodiment of the invention, the treatment according to the invention can be used in vivo and ex vivo in suffering organs to treat ischemia / reperfusion injuries, control inflammation and allow its recovery, or even its repair and regeneration.

[0089] The possible photonic delivery routes vary depending on the medical-surgical situations:

[0090] • Intra-tissue or interstitial;

[0091] • endocavitary;

[0092] • endovascular.

[0093] The wavelengths used are between 500 nm and 1100 nm, with a power ranging from 1 mW to 4000 mW. The treatment can be carried out in intermittent or sequential cycles or continuously for a short or long term via an implantable diffuser.

[0094] 1. Intramyocardial device for QBM treatment of acute cardiac ischemia / reperfusion injury

[0095] By using optimized treatment conditions according to the invention, it is possible to "precondition" the cardiac muscle that has undergone hypoxia, to prepare it for reoxygenation. This makes it possible to avoid the paradox of reoxygenation which is deleterious for the cardiac muscle ("oxygen paradox"), because it would induce an overload of ROS.

[0096] Furthermore, since QBM is capable of limiting the process of inflammation and fibrous healing following ischemic accidents, cellular metabolic pathways can be preserved by QBM treatment, thus promoting organ regeneration by maintaining the functionality of cells undergoing stress.

[0097] The system according to the invention comprises:

[0098] • a laser source (reference 1, Figure 4), an electro-medical device, which produces and delivers photons with parameters (time and power) adjustable by the user;

[0099] • at least one fiber optic distributor (reference 2, Figure 4), which allows the transmission of light to the diffusers;

[0100] • at least one diffuser (reference 3, Figure 4) crimped at its end with a detachable needle which will allow the surgeon to insert the diffuser through the heart muscle. Once the diffuser is in place, the needle will be detached.

[0101] Figure 4 contains a schematic illustrating the intramyocardial device for QBM treatment of acute cardiac ischemia / reperfusion injuries. This device is composed of the Laser source 1 , the fiber optic distributors

[0102] 2, diffusers 3. The intramyocardial placement of the fiber optic distributor is carried out surgically or by coelioscopy.

[0103] The treatment is carried out in pre-, per-, and post-reperfusion conditioning with a temporal evolution of the power emitted by the source so that the cardiomyocytes receive the effective therapeutic dose.

[0104] Possibility of performing single or multiple irradiation.

[0105] Acute or chronic treatment.

[0106] It is a temporary or non-implantable medical device, sterile and for single use.

[0107] A variant of the diffuser (patch / band) can be used intrathoracically around the heart mass for the treatment of ischemia / reperfusion injuries.

[0108] Figure 5 contains a schematic illustrating the intrathoracic device for QBM treatment of acute cardiac ischemia / reperfusion injuries. This device is composed of the laser source 1 , the fiber optic distributor 2 , the homogeneous diffusion patch / band 3.

[0109] 2. Endoventricular medical device for QBM treatment of acute cardiac ischemia / reperfusion injury

[0110] This involves the placement of one or more diffusers in the left ventricle via a minimally invasive percutaneous route under fluoroscopy:

[0111] • Radial or femoral arterial / venous access:

[0112] • Placement of an introducer using the Seldinger technique;

[0113] • Navigation to the ventricle to place at least: o a self-expanding balloon type diffuser o or a diffuser inserted into the ventricular cavity o or a diffuser inserted into the ventricular wall.

[0114] The treatment is carried out in pre-, per-, and post-reperfusion conditioning with a temporal evolution of the power emitted by the source so that the cardiomyocytes receive the effective therapeutic dose.

[0115] Possibility of performing single or multiple irradiation.

[0116] Figure 6 contains a schematic illustrating the endoventricular medical device for QBM treatment of acute cardiac ischemia / reperfusion injuries. This device is composed of the Laser source 1 , the fiber optic distributor

[0117] 2, of the diffuser in cavity 3.

[0118] Another variant of this device is an embedded and autonomous system. In other words, the single assembly, consisting of the diffuser and the laser source, is implanted in the ventricle.

[0119] 3. Intracoronary device for QBM treatment of acute cardiac ischemia / reperfusion injury

[0120] Placement of at least one diffuser in the coronary arteries by minimally invasive percutaneous route under fluoroscopy:

[0121] • Radial or femoral arterial access;

[0122] • Placement of an introducer using the Seldinger technique;

[0123] • Navigation to the coronaries to place at least one diffuser.

[0124] The treatment is carried out in pre-, per-, and post-reperfusion conditioning with a temporal evolution of the power emitted by the source so that the cardiomyocytes receive the effective therapeutic dose. Possibility of carrying out a single or multiple irradiation.

[0125] Figure 7A contains a schematic illustrating the intracoronary device for QBM treatment of acute cardiac ischemia / reperfusion injuries. This device is composed of the laser source 1, the fiber optic distributor 2, the diffuser 3.

[0126] 4. Devices for the treatment of specific organs by QBM

[0127] -Inner ear for the management of acute cochleovestibular syndromes and age-related degeneration

[0128] Another variation of this device is an on-board, stand-alone system.

[0129] In other words, the device, illustrated in Figure 7B, comprises the diffuser 3 of the laser source, implanted in the ear.

[0130] -Female genital system for the management of endometriosis, dysmenorrhea, illustrated in Figure 7C.

[0131] -Male genital apparatus for the management of erectile dysfunction, shown in Figure 7D.

[0132] -Ex vivo treatment of ischemia / reperfusion injuries during transplantation

[0133] Another application of ex vivo QBM treatment to the transplanted heart and by extension to other transplanted organs (lung, liver, kidney, etc.) to reduce the consequences of ischemia times during reperfusion of transplanted organs, accelerate and improve the functional recovery of transplanted organs.

[0134] Figure 8 contains a schematic illustrating the device for ex vivo QBM treatment of ischemia / reperfusion injuries. This device comprises the laser source 1, the fiber optic distributor 2, a homogeneous diffusion chamber

[0135] 5.

Claims

Claims 1. Medical device system for Quantum Bio Modulation (QBM) treatment of biological tissue cells, comprising: - a laser source configured to produce photons according to adjustable wavelength, time and power parameters; - at least one optical distributor; and - at least one diffuser.

2. The medical device of claim 1, wherein the at least one optical distributor comprises an optical fiber inserted into a central venous line type multi-lumen catheter.

3. The medical device of claim 2, wherein the at least one optical dispenser is further configured to have one or more of a list of characteristics including being implantable, being temporary, sterile, single use.

4. The medical device according to claim 1, wherein the at least one optical distributor comprises a plurality of optical distributors, and the plurality of optical distributors is mounted in an illumination system configured to allow illumination of tubing or an oxygenation chamber of an extracorporeal circulation circuit.

5. The medical device of claim 1, wherein the at least one optical dispenser comprises a plurality of optical dispensers, and each of the plurality of optical dispensers is crimped with a detachable needle configured for insertion of the optical dispenser through a heart muscle.

6. The medical device according to any one of claims 1 to 5, wherein the power parameters are adjustable between 1 mW and 4000 mW, and wavelengths used are in a range starting at 500 nm and ending at 1100 nm.

7. Method for photonic stimulation of a biological tissue according to Quantum BioModulation (QBM), comprising the steps of: generating photons according to adjustable time and power parameters by means of a laser source; placing at least one optical distributor with an optical input for receiving the photons generated by the laser source and an optical output of the optical distributor oriented towards the biological tissue; delivering at least a portion of the generated photons onto the biological tissue.

8. The photonic stimulation method of claim 7, further comprising: providing the biological tissue suspended in a liquid medium; presenting the liquid medium in a closed container or through conduit; and configuring the optical output of the optical dispenser to contact the liquid medium.

Images